Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

PRAX

Praxis Precision Medicines Inc

Dec 13 • 04:00PM ET

70.18

Dollar change -0.82
Percentage change -1.15	%

Healthcare • Biotechnology • USA • NASD

Peers: SAGE ITCI ACAD NBIX BHVN AXSM VNDA RLMD CYBN MNMD

| Held by: VTI IWM XBI VXF IWO DWAS SCHA VTWO PINK VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-10.30	Insider Own	7.20%	Shs Outstand	17.79M	Perf Week	0.47%
Market Cap	1.29B	Forward P/E	-	EPS next Y	-11.47	Insider Trans	-0.99%	Shs Float	17.30M	Perf Month	-14.12%
Income	-151.02M	PEG	-	EPS next Q	-2.85	Inst Own	95.25%	Short Float	8.47%	Perf Quarter	20.40%
Sales	1.60M	P/S	808.06	EPS this Y	45.43%	Inst Trans	3.78%	Short Ratio	4.91	Perf Half Y	80.09%
Book/sh	21.52	P/B	3.26	EPS next Y	-12.42%	ROA	-57.75%	Short Interest	1.47M	Perf Year	318.74%
Cash/sh	19.38	P/C	3.62	EPS next 5Y	-14.60%	ROE	-64.34%	52W Range	14.77 - 86.93	Perf YTD	214.99%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-10.28%	ROI	-39.42%	52W High	-19.27%	Beta	2.70
Dividend TTM	-	Quick Ratio	10.96	Sales past 5Y	0.00%	Gross Margin	73.71%	52W Low	374.99%	ATR (14)	4.82
Dividend Ex-Date	-	Current Ratio	10.96	EPS Y/Y TTM	69.41%	Oper. Margin	-10219.00%	RSI (14)	46.37	Volatility	7.35% 6.63%
Employees	82	Debt/Eq	0.00	Sales Y/Y TTM	-16.93%	Profit Margin	-9409.22%	Recom	1.30	Target Price	162.60
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-0.88%	Payout	-	Rel Volume	0.63	Prev Close	71.00
Sales Surprise	-8.40%	EPS Surprise	-38.26%	Sales Q/Q	-35.47%	Earnings	Nov 06 BMO	Avg Volume	298.60K	Price	70.18
SMA20	-4.27%	SMA50	-3.01%	SMA200	23.77%	Trades		Volume	186,848	Change	-1.15%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-05-24	Initiated	Oppenheimer	Outperform	$134
Jun-24-24	Initiated	Needham	Buy	$145
Jun-18-24	Initiated	Guggenheim	Buy	$155
May-01-24	Initiated	Robert W. Baird	Outperform	$117
Sep-19-23	Initiated	Truist	Buy	$10
Jun-06-22	Downgrade	Wedbush	Outperform → Neutral	$4
Dec-16-21	Initiated	H.C. Wainwright	Buy	$48
Aug-26-21	Initiated	BofA Securities	Buy	$28
Apr-26-21	Initiated	William Blair	Outperform
Nov-11-20	Initiated	Wedbush	Outperform	$40
Nov-10-20	Initiated	Piper Sandler	Overweight	$65
Nov-10-20	Initiated	Evercore ISI	Outperform	$55
Nov-10-20	Initiated	Cowen	Outperform

Show Previous Ratings

Dec-05-24 08:30AM	GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners (Business Wire) -8.18%
Dec-03-24 08:00AM	Praxis Precision Medicines to Present at Upcoming December Investor Conferences (GlobeNewswire) -7.39%
Nov-26-24 08:00AM	Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting (GlobeNewswire) +6.67%
Nov-07-24 02:08AM	Praxis Precision Medicines Inc (PRAX) Q3 2024 Earnings Call Highlights: Strong Cash Position ... (GuruFocus.com)
Nov-06-24 05:00PM	Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences (GlobeNewswire)
08:45AM	Loading…
08:45AM	Praxis Precision Medicines, Inc. (PRAX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-01-24 08:00AM	Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024 (GlobeNewswire)
Oct-15-24 04:57PM	Health Care Roundup: Market Talk (The Wall Street Journal)
Oct-12-24 10:18AM	Praxis Precision Medicines, Inc (PRAX): A Small-Cap Leader in Biopharmaceuticals (Insider Monkey)
Oct-04-24 09:01AM	Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last? (Zacks)
Sep-26-24 08:00AM	Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress (GlobeNewswire)
Sep-23-24 09:37PM	Perceptive Advisors LLC Adjusts Stake in Praxis Precision Medicines Inc (GuruFocus.com) -8.06%
Sep-05-24 08:00AM	Praxis Precision Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-04-24 08:00AM	Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations (GlobeNewswire) +9.62%
12:18PM	Loading…
Sep-03-24 12:18PM	Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug (Benzinga)
07:30AM	Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine (GlobeNewswire)
Sep-02-24 05:00PM	Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024 (GlobeNewswire)
Aug-15-24 12:00PM	Praxis Precision Medicines (PRAX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +6.32%
Aug-13-24 08:20AM	Praxis Precision Medicines, Inc. (PRAX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-05-24 04:01PM	Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024 (GlobeNewswire) -5.74%
Jun-21-24 03:32AM	Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains? (Zacks)
Jun-20-24 04:08PM	Jazz Dives But Key Rival Praxis Surges On Essential Tremor Drug Failure (Investor's Business Daily) +6.42%
10:08AM	Jazz Dives And Takes Praxis With It On Essential Tremor Drug Failure (Investor's Business Daily)
Jun-04-24 05:00PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-17-24 08:00AM	Praxis Precision Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-13-24 11:53AM	PRAX Stock Earnings: Praxis Precision Medicine Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -7.36%
07:00AM	Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-10-24 08:00AM	Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024 (GlobeNewswire)
04:45PM	Loading…
May-03-24 04:45PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-02-24 09:55AM	Wall Street Analysts See a 144.74% Upside in Praxis Precision Medicines (PRAX): Can the Stock Really Move This High? (Zacks)
May-01-24 07:10AM	Baird Initiates Praxis Precision Medicines With Outperform Rating, $117 Price Target (MT Newswires)
Apr-12-24 08:00AM	Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting (GlobeNewswire)
Apr-11-24 12:00PM	Praxis Precision Medicines (PRAX) Upgraded to Buy: Here's Why (Zacks) +6.43%
Apr-05-24 09:00AM	Praxis Precision Medicines to Participate in Upcoming April Conferences (GlobeNewswire)
Apr-02-24 05:00PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.17%
Mar-29-24 06:23AM	Health Care Roundup: Market Talk (The Wall Street Journal)
Mar-28-24 12:20AM	Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering (GlobeNewswire)
Mar-27-24 04:01PM	Praxis Precision Medicines, Inc. Announces Proposed Public Offering (GlobeNewswire)
10:53AM	Praxis (PRAX) Surges on Positive Epilepsy Study Results (Zacks)
Mar-26-24 04:14PM	Top 1% Biotech, Praxis, Releases 'Fireworks' And Catapults To Year-High (Investor's Business Daily) +23.13%
09:21AM	Praxis, A Top 1% Stock, Soars To Year-High After Epilepsy Treatment Scores Big (Investor's Business Daily)
06:30AM	Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients (GlobeNewswire)
Mar-25-24 04:01PM	Praxis Precision Medicines to Host PRAX-628 Program Update (GlobeNewswire) -6.26%
Mar-08-24 12:00PM	What Makes Praxis Precision Medicines, Inc. (PRAX) a Strong Momentum Stock: Buy Now? (Zacks)
Mar-07-24 01:31PM	Praxis Precision Medicines Inc (PRAX) Reports Full-Year 2023 Financial Results and Corporate Updates (GuruFocus.com)
Mar-06-24 09:55AM	Wall Street Analysts Think Praxis Precision Medicines, Inc. (PRAX) Could Surge 134.35%: Read This Before Placing a Bet (Zacks) +8.35%
Mar-05-24 08:10AM	Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Mar-01-24 08:00AM	Praxis Precision Medicines to Participate in TD Cowen's 44th Annual Health Care Conference (GlobeNewswire) +5.90%
Feb-02-24 04:00PM	Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-11-24 07:30AM	Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering (GlobeNewswire) +11.66%
Jan-10-24 04:19PM	Praxis Precision Medicines, Inc. Announces Proposed Public Offering (GlobeNewswire)
Jan-09-24 04:57PM	Praxis Precision Medicines, Inc. (PRAX) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +24.96%
Jan-08-24 08:00AM	Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio (GlobeNewswire) +24.85%
Jan-05-24 09:55AM	Praxis Precision Medicines, Inc. (PRAX) Just Flashed Golden Cross Signal: Do You Buy? (Zacks) -7.12%
08:00AM	Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China (GlobeNewswire)
Nov-30-23 09:55AM	Wall Street Analysts Believe Praxis Precision Medicines, Inc. (PRAX) Could Rally 494.95%: Here's is How to Trade (Zacks)
Nov-28-23 07:00AM	Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings (GlobeNewswire) -9.09%
Nov-21-23 04:00PM	Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire) -13.01% +5.61%
Nov-16-23 08:00AM	Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies (GlobeNewswire)
Nov-14-23 09:35AM	Praxis Precision Medicines, Inc. (PRAX) Loses -32.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +5.48%
Nov-07-23 08:00AM	Praxis Precision Medicines Inc (PRAX) Reports Q3 2023 Financial Results (GuruFocus.com) +6.51%
07:00AM	Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-02-23 08:00AM	Praxis Precision Medicines to Present at Truist Securities BioPharma Symposium (GlobeNewswire) +5.41%
Oct-02-23 01:17PM	Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day (GlobeNewswire)
Sep-27-23 04:15PM	Praxis Precision Medicines To Host Hybrid R&D Day on Monday, October 2, 2023 (GlobeNewswire) +10.74%
Sep-07-23 08:00AM	Praxis Precision Medicines to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) +5.11%
Aug-31-23 08:00AM	Praxis Precision Medicines to Present Data from Epilepsy Portfolio at the 35th International Epilepsy Congress (GlobeNewswire) +5.76%
Aug-28-23 07:00AM	Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress (GlobeNewswire)
Aug-17-23 10:04AM	Billionaire Steve Cohen Loads Up on These 2 Strong Buy Penny Stocks Heres Why Wall Street Sees Over 500% Upside Potential (TipRanks) +18.58%
Aug-11-23 07:00AM	The past year for Praxis Precision Medicines (NASDAQ:PRAX) investors has not been profitable (Simply Wall St.)
Aug-09-23 07:00AM	Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-08-23 07:00AM	Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide (GlobeNewswire)
Aug-07-23 07:00AM	Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study (GlobeNewswire)
Aug-03-23 04:12PM	Praxis Precision Medicines to Participate at the 2023 Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Jul-14-23 10:20AM	Following a 63% decline over last year, recent gains may please Praxis Precision Medicines, Inc. (NASDAQ:PRAX) institutional owners (Simply Wall St.) -13.53%
Jun-22-23 07:00AM	Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities (GlobeNewswire)
Jun-17-23 09:41AM	Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth? (Simply Wall St.)
Jun-15-23 11:58PM	Praxis Precision Medicines, Inc. Announces Pricing of $59.1 Million Public Offering (GlobeNewswire) +6.47% +18.23%
04:01PM	Praxis Precision Medicines, Inc. Announces Proposed Public Offering (GlobeNewswire)
Jun-09-23 07:00AM	Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA (GlobeNewswire)
Jun-02-23 09:00AM	Praxis Precision Medicines to Present at the 2023 Jefferies Healthcare Conference (GlobeNewswire) +15.15%
May-11-23 01:12PM	Praxis Precision Medicines Says PRAX-628 Can Potentially Be The Best-In-Class Treatment For Focal Epilepsy (Benzinga)
07:30AM	Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
06:55AM	Praxis Precision Medicines Announces Positive Topline Results from PRAX-628 Phase 1 Study Enabling Best-in-Class Profile (GlobeNewswire)
May-07-23 09:22AM	Pleasing Signs As A Number Of Insiders Buy Praxis Precision Medicines Stock \ (Simply Wall St.)
Apr-19-23 08:00AM	Praxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting (GlobeNewswire)
Apr-17-23 08:00AM	Praxis Precision Medicines Announces Upcoming Ulixacaltamide Presentations & Events (GlobeNewswire) +6.00%
Apr-06-23 09:00AM	Praxis Precision Medicines to Present at 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-03-23 04:05PM	Praxis Precision Medicines to Present at Upcoming Investor Conferences (GlobeNewswire) -65.87% +11.39%
11:05AM	Despite Trial Failure Praxis Still Seeks Advancing Essential Tremor Program Into Phase 3 Study (Benzinga)
07:30AM	Praxis Precision Medicines Announces Topline Results from the Essential1 Study of Ulixacaltamide for the Treatment of Essential Tremor and Continued Advancement of Program to Phase 3 (GlobeNewswire)
Feb-07-23 08:00AM	Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Dec-13-22 04:01PM	Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration (GlobeNewswire) +13.18%
Nov-28-22 04:05PM	Praxis Precision Medicines to Present at the American Epilepsy Society 2022 Annual Meeting (GlobeNewswire) +9.18%
08:00AM	Praxis Precision Medicines to Advance PRAX-562 Phase 2 Study in Pediatric Patients with Developmental and Epileptic Encephalopathies (GlobeNewswire)
Nov-09-22 04:01PM	Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire) -7.08% -5.83%
05:42AM	Positive week for Praxis Precision Medicines, Inc. (NASDAQ:PRAX) institutional investors who lost 89% over the past year (Simply Wall St.)

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. It is a targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nemiroff Alex	General Counsel and Secretary	Nov 14 '24	Option Exercise	56.94	7,583	431,776	18,540	Nov 15 09:30 PM
Nemiroff Alex	General Counsel and Secretary	Nov 14 '24	Sale	80.20	8,239	660,827	10,301	Nov 15 09:30 PM
Mastrocola Lauren	Principal Accounting Officer	Nov 14 '24	Option Exercise	56.94	4,374	249,056	10,801	Nov 15 09:30 PM
Mastrocola Lauren	Principal Accounting Officer	Nov 14 '24	Sale	81.78	5,188	424,318	5,613	Nov 15 09:30 PM
Mastrocola Lauren	Officer	Nov 14 '24	Proposed Sale	81.77	5,189	424,316		Nov 14 02:32 PM
Nemiroff Alex	Officer	Nov 14 '24	Proposed Sale	80.20	8,240	660,832		Nov 14 01:45 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PRAX

Praxis Precision Medicines Inc

Upgrade your FINVIZ experience